Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of SOM230 for Treatment of Graves’ Ophthalmopathy
KCT0001645Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Sep 2015
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of pasireotide LAR in Graves' ophthalmopathy (TED), sponsored by Novartis. Started Sep 2015; status: recruiting.
02
Drugs
pasireotide LAR
03
Conditions
Graves' ophthalmopathy (TED)
Beyond the preview
Go deeper on KCT0001645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0001645.